Valuation: GlucoTrack, Inc.

Market Cap 966K 858K 801K 730K 1.38M 92.84M 1.39M 9.69M 3.76M 47.46M 3.63M 3.55M 152M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -2.97M -2.64M -2.46M -2.25M -4.24M -286M -4.28M -29.82M -11.55M -146M -11.16M -10.91M -469M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
92.02%
Yield 2024 *
-
Yield 2025 -
1 day-14.18%
1 week-33.52%
Current month-26.22%
1 month-65.72%
3 months-74.79%
6 months-90.62%
Current year-97.92%
1 week 1.15
Extreme 1.15
1.95
1 month 1.15
Extreme 1.15
3.31
Current year 1.15
Extreme 1.15
63.6
1 year 1.15
Extreme 1.15
136.29
3 years 1.15
Extreme 1.15
89,100.09
5 years 1.15
Extreme 1.15
495,000.5
10 years 1.15
Extreme 1.15
7,020,007.02
Manager TitleAgeSince
Chief Executive Officer 55 2026-07-13
Director of Finance/CFO 66 2025-01-27
Chief Operating Officer - 2025-01-31
Director TitleAgeSince
Director/Board Member 56 2023-08-24
Chairman 64 2024-02-12
Director/Board Member 78 2024-06-13
Date Insider Type Main position Quantity % Market Cap. Importance
3/26/25 Free

Director

4,490 0.0431%
3/25/25 Free

Director

8,747 0.0840%
3/25/25 Free

Director

5,473 0.0526%
Change 5-day change 1-year change 3-year change Capi.($)
-14.18%-33.52%-98.79%-99.99% 966K
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+21.92%+74.60% 57.39B
+0.89%-0.63%+4.28%+34.51% 47.64B
+0.36%+0.81%+352.17%+689.61% 44.29B
-0.96%-4.50%+26.36%+33.18% 42.5B
-0.20%-0.77%+3.74%+100.60% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.63%+19.50% 28.53B
+0.05%-1.64%-7.28%-14.06% 24.34B
Average -1.62%-3.88%+39.07%+98.25% 39.05B
Weighted average by Cap. +0.12%-0.84%+58.76%+129.91%

Financials

2024 2025
Net sales - -
Net income -22.6M -20.08M -18.74M -17.08M -32.21M -2.17B -32.51M -227M -87.88M -1.11B -84.84M -83M -3.56B -19.39M -17.23M -16.08M -14.65M -27.64M -1.86B -27.9M -195M -75.4M -953M -72.79M -71.21M -3.06B
Net Debt -5.35M -4.75M -4.44M -4.04M -7.63M -514M -7.7M -53.69M -20.81M -263M -20.09M -19.65M -844M -3.94M -3.5M -3.26M -2.98M -5.61M -378M -5.66M -39.51M -15.31M -193M -14.78M -14.46M -621M
Logo GlucoTrack, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
15
Date Price Change Volume
26-10-02 US$1.210 -14.18% 301,423
26-10-01 US$1.410 -14.02% 634,116
26-09-30 US$1.640 -5.75% 1,180,242
26-09-29 US$1.740 -3.33% 269,070
26-09-28 US$1.800 -1.10% 519,678
  1. Stock Market
  2. Stocks
  3. GCTK Stock